# expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma

Source: [Science Media Centre](https://www.sciencemediacentre.org/expert-reaction-to-abstract-about-daraxonrasib-plus-gnp-for-metastatic-pancreatic-adenocarcinoma/) · 2026-11-19 · Science & Society
Page: https://themorning.science/story/expert-reaction-to-abstract-about-daraxonrasib-plus-gnp-for-metastatic-pancreati-679c75ffa965029c
Kind: research · Impact: medium

## In brief

- An abstract presented at EORTC-NCI-AACR 2026 reports on daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma.
- Shivan Sivakumar, Professor of Translational Oncology at the University of Birmingham, described the results as very encouraging.

## Why it matters

The source covers early expert reaction to a treatment combination tested in metastatic pancreatic adenocarcinoma, a disease where the expert called the results encouraging. Only the abstract and a brief expert reaction are available, so the full data are not yet known.

## Coverage

- [expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma](https://www.sciencemediacentre.org/expert-reaction-to-abstract-about-daraxonrasib-plus-gnp-for-metastatic-pancreatic-adenocarcinoma/) — Science Media Centre, 2026-11-19

Tags: pancreatic cancer, metastatic cancer, oncology, daraxonrasib, clinical research

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
